抗血管内皮増殖因子（抗VEGF）治療薬の世界市場

抗血管内皮増殖因子（抗VEGF）治療薬の世界市場は2030年までに米国で135億米ドルに達する見込み

2024年に123億米ドルと推定される抗血管内皮増殖因子（抗VEGF）治療薬の世界市場は、2024年から2030年にかけてCAGR 1.6%で成長し、2030年には135億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである黄斑浮腫疾患は、CAGR 2.2%を記録し、分析期間終了時には55億米ドルに達すると予測されます。糖尿病性網膜症疾患セグメントの成長率は、分析期間中CAGR 1.2%と推定されます。

米国市場は33億米ドルと推定、中国はCAGR 3.2％で成長予測

米国の抗血管内皮増殖因子（抗VEGF）治療薬市場は2024年に33億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに25億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と1.4%と予測されています。欧州では、ドイツがCAGR約0.9%で成長すると予測されています。

世界の抗血管内皮増殖因子（抗VEGF）治療薬市場- 主要動向と促進要因のまとめ

抗VEGF治療薬が視力障害やがん治療の主流になりつつあるのはなぜか？

抗血管内皮増殖因子（抗VEGF）治療薬は、加齢黄斑変性症（AMD）、糖尿病性網膜症、様々ながんなど、血管の異常な成長を特徴とする疾患の治療において、画期的な薬剤として登場しました。VEGFは血管新生-新しい血管の形成-を司る重要なシグナル伝達タンパク質であり、創傷治癒のような生理的過程と、過剰あるいは異常な血管形成が病気の進行につながる病的状態の両方において重要な役割を果たしています。抗VEGF療法はこの経路を阻害することによって作用し、有害な血管の形成を阻止または逆転させる。眼科領域では、ラニビズマブ、ベバシズマブ、アフリベルセプトなどの抗VEGF薬の硝子体内注射が網膜疾患の治療に革命をもたらし、世界中で数百万人の患者の視力を大幅に維持、さらには改善しています。腫瘍学では、ベバシズマブのような抗VEGF薬が化学療法と併用され、腫瘍への血液供給を遮断し、腫瘍の成長と転移を抑制します。視力回復と延命治療の両方に応用できることから、抗VEGF療法は現代医学の最前線に位置づけられています。その有効性、比較的よく理解されているメカニズム、適応の拡大により、抗VEGF療法は複数の治療領域にわたる標準的な治療プロトコールに組み込まれています。人口が高齢化し、糖尿病やがんのような慢性疾患が蔓延するにつれて、これらの生物学的製剤の臨床的必要性は増大し続け、世界の医薬品事情においてその重要な役割が強化されています。

ドラッグ・デザインとデリバリーの革新は、抗VEGF療法の臨床的可能性をどのように高めているか？

抗VEGF薬の製剤、デリバリー、薬力学における継続的な技術革新は、その治療可能性を急速に拡大し、患者の転帰を改善しています。眼科領域における主な課題の1つは、頻繁に硝子体内注射を行う必要性であり、多くの場合、毎月または隔月に行われるため、患者やヘルスケアシステムに大きな負担を強いています。これに対し、注射の頻度を減らすための徐放性デリバリー・プラットフォームの開発が進められています。ラニビズマブのポートデリバリーシステム（PDS）や生分解性インプラントのような革新的な薬剤は、数カ月にわたって持続的に薬剤を放出し、患者のアドヒアランスと利便性を大幅に改善します。さらに、ブロルシズマブやファリシマブのような新世代の抗VEGF分子は、より高い結合親和性、より長い作用時間、デュアルターゲットメカニズムを持つように設計されており、有効性をさらに最適化しています。がん領域では、抗VEGF薬と免疫チェックポイント阻害薬やチロシンキナーゼ阻害薬（TKI）を統合した併用レジメンが相乗効果を示し、治療抵抗性がんに新たな希望をもたらしています。また、バイオシミラーの台頭も市場に影響を与え始めており、低・中所得国でのアクセシビリティを拡大しうる費用対効果の高い選択肢を提供しています。一方、個別化医療とバイオマーカー主導型アプローチの進歩は、より優れた患者層別化を可能にし、抗VEGF療法の恩恵を最も受けそうな患者が確実に治療を受けられるようにしています。人工知能や画像解析も、より正確に疾患の進行をモニターし、臨床医が投与レジメンを微調整するのに役立っています。製薬研究がこれらの生物学的製剤の安全性、特異性、寿命の改良に焦点を当て続けるにつれて、抗VEGF療法はより患者にやさしく、多様な臨床環境に広く適用できるソリューションへと変化しています。

ヘルスケアシステムと人口動態の動向は抗VEGF療法の採用をどのように促進しているか？

世界中のヘルスケアシステムは、早期介入と慢性疾患管理をますます優先するようになっており、抗VEGF治療薬の需要に直接拍車をかけている動向です。眼科領域では、加齢黄斑変性は60歳以上の視力低下の主な原因であり、世界人口の急速な高齢化に伴い、リスクを抱える人の数は飛躍的に増加しています。同様に、糖尿病の世界の有病率の上昇により、糖尿病性網膜症や糖尿病性黄斑浮腫が急増しており、いずれも抗VEGF薬で効果的に治療されています。生産性の低下から依存性の増加まで、視覚障害が社会経済的負担となることから、医療制度は予防と視力維持の治療に投資せざるを得ず、抗VEGF療法は優先順位の高い治療法として位置づけられています。抗VEGF薬が結腸直腸がん、腎がん、肺がん、その他のがんの第一選択および第二選択治療レジメンに組み込まれるにつれて、がん治療への応用も勢いを増しています。保険償還範囲の拡大、臨床ガイドラインへの盛り込み、専門医による広範な採用により、これらの治療薬へのアクセスはさらに向上しています。さらに、ヘルスケア提供モデルは、抗VEGF治療を効率的に実施できる眼科専門クリニックや輸液センターを含むように進化しています。公衆衛生啓発キャンペーンや診断能力の向上により、網膜や腫瘍の状態の早期発見が可能になり、治療対象者が拡大しています。また、患者支援活動やデジタルヘルスツールによって、より早く治療を受け、処方されたレジメンをより忠実に守ることができるようになっています。世界の保健衛生の優先事項が慢性的な非感染性疾患の管理にシフトする中、抗VEGF療法は集学的治療アプローチの中心となりつつあり、何百万人もの人々の生活の質と長期的転帰を改善しています。

抗VEGF治療薬市場の世界的成長を促進する主な要因は何か？

抗VEGF治療薬市場の成長は、臨床ニーズ、人口動態の勢い、技術革新、市場拡大戦略の収束によってもたらされます。主な促進要因は、網膜疾患と固形腫瘍の負担の増大であり、これらはいずれも世界的に公衆衛生上の大きな課題となっています。視力の測定可能な改善と腫瘍の抑制をもたらす抗VEGF療法の能力により、抗VEGF療法は多くの適応症においてゴールドスタンダード治療として確立しています。主要企業に支えられた強力な研究開発パイプラインは、新しい薬剤や改良された薬剤を市場に送り出し続け、製品ライフサイクルを延ばし、新たな患者集団を獲得しています。迅速承認や希少疾病用医薬品の指定を含む規制当局の支援により、特に希少な眼疾患や抵抗性がんにおいて、新規製剤の市場投入までの時間が短縮されています。バイオシミラーの台頭は、特に先発品の生物製剤の経済的負担が障壁となっている新興諸国において、治療費を引き下げることでアクセスの民主化をもたらすと期待されています。バイオテクノロジー企業と大手ヘルスケアプロバイダーとの戦略的パートナーシップは、流通網の拡大と抗VEGF薬の幅広い治療アルゴリズムへの統合に役立っています。さらに、患者の意識の高まり、デジタルヘルス・プラットフォームの普及、価値観に基づく治療へのシフトは、早期診断と継続的治療のインセンティブを整えつつあります。AIを活用した画像診断やリアルタイムのデータモニタリングなどの技術的なイネーブラーは、治療の精度と有効性をさらに高めています。これらの相互関連力の結果、世界の抗VEGF治療薬市場は力強い成長軌道にあり、今後10年間でその範囲と規模が大幅に拡大する見込みです。

セグメント

疾患（黄斑浮腫疾患、糖尿病網膜症疾患、網膜静脈閉塞症疾患、加齢黄斑変性疾患）、エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、その他エンドユーザー）

調査対象企業の例（注目の合計42社）

• AbbVie Inc.
• Alcon Inc.
• Allergan plc
• Amgen Inc.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• Coherus BioSciences, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market to Reach US$13.5 Billion by 2030

The global market for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics estimated at US$12.3 Billion in the year 2024, is expected to reach US$13.5 Billion by 2030, growing at a CAGR of 1.6% over the analysis period 2024-2030. Macular Edema Disease, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the Diabetic Retinopathy Disease segment is estimated at 1.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 3.2% CAGR

The Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market - Key Trends & Drivers Summarized

Why Are Anti-VEGF Therapeutics Becoming a Mainstay in the Treatment of Vision and Cancer Disorders?

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapeutics have emerged as transformative agents in the treatment of diseases characterized by abnormal blood vessel growth, including age-related macular degeneration (AMD), diabetic retinopathy, and various forms of cancer. VEGF is a key signaling protein responsible for angiogenesis-the formation of new blood vessels-which plays a vital role in both physiological processes like wound healing and pathological conditions where excessive or abnormal vessel formation leads to disease progression. Anti-VEGF therapies work by inhibiting this pathway, thereby preventing or reversing the formation of harmful blood vessels. In ophthalmology, intravitreal injections of anti-VEGF agents such as ranibizumab, bevacizumab, and aflibercept have revolutionized treatment for retinal diseases, significantly preserving and even improving vision in millions of patients worldwide. In oncology, anti-VEGF drugs like bevacizumab are used in combination with chemotherapy to cut off the blood supply to tumors, inhibiting their growth and spread. The dual applicability in both vision-saving and life-extending treatments has placed Anti-VEGF therapies at the forefront of modern medicine. Their effectiveness, relatively well-understood mechanisms, and expanding indications have driven their integration into standard treatment protocols across multiple therapeutic areas. As populations age and chronic diseases like diabetes and cancer become more prevalent, the clinical necessity for these biologics continues to grow, reinforcing their essential role in the global pharmaceutical landscape.

How Are Innovations in Drug Design and Delivery Enhancing the Clinical Potential of Anti-VEGF Therapies?

Ongoing innovation in the formulation, delivery, and pharmacodynamics of anti-VEGF agents is rapidly expanding their therapeutic potential and improving patient outcomes. One of the main challenges in ophthalmology has been the need for frequent intravitreal injections-often monthly or bi-monthly-creating a substantial burden on patients and healthcare systems. In response, extended-release delivery platforms are being developed to reduce injection frequency. Innovations such as the Port Delivery System (PDS) for ranibizumab and biodegradable implants are offering sustained drug release over several months, significantly improving patient adherence and convenience. Additionally, newer-generation anti-VEGF molecules like brolucizumab and faricimab are engineered for greater binding affinity, longer duration of action, and dual-targeting mechanisms-further optimizing efficacy. In oncology, combination regimens that integrate anti-VEGF agents with immune checkpoint inhibitors or tyrosine kinase inhibitors (TKIs) are demonstrating synergistic effects, offering new hope for treatment-resistant cancers. The rise of biosimilars is also beginning to impact the market, providing cost-effective alternatives that could expand accessibility in low- and middle-income countries. Meanwhile, advancements in personalized medicine and biomarker-driven approaches are enabling better patient stratification, ensuring that those most likely to benefit from anti-VEGF therapies receive them. Artificial intelligence and imaging analytics are also being used to monitor disease progression more accurately, helping clinicians fine-tune dosing regimens. As pharmaceutical research continues to focus on refining the safety, specificity, and longevity of these biologics, anti-VEGF therapies are being transformed into more patient-friendly and widely applicable solutions across diverse clinical settings.

How Are Healthcare Systems and Demographic Trends Driving the Adoption of Anti-VEGF Therapies?

Healthcare systems around the world are increasingly prioritizing early intervention and chronic disease management-trends that are directly fueling the demand for anti-VEGF therapeutics. In ophthalmology, age-related macular degeneration is the leading cause of vision loss in people over 60, and with the global population aging rapidly, the number of individuals at risk is growing exponentially. Similarly, the escalating global prevalence of diabetes is resulting in a surge in diabetic retinopathy and diabetic macular edema, both of which are treated effectively with anti-VEGF agents. The socioeconomic burden of visual impairment-from lost productivity to increased dependency-has compelled health systems to invest in preventive and sight-preserving treatments, positioning anti-VEGF therapies as high-priority interventions. Oncology applications are also gaining momentum as anti-VEGF drugs become embedded in first-line and second-line treatment regimens for colorectal, renal, lung, and other cancers. Increased reimbursement coverage, inclusion in clinical guidelines, and widespread specialist adoption are further enhancing access to these therapies. Moreover, healthcare delivery models are evolving to include specialized eye care clinics and infusion centers that can efficiently administer anti-VEGF treatments. Public health awareness campaigns and improved diagnostic capabilities are enabling earlier detection of retinal and tumor conditions, expanding the eligible treatment population. Patient advocacy and digital health tools are also empowering individuals to seek care sooner and adhere more closely to prescribed regimens. As global health priorities shift toward managing chronic, non-communicable diseases, anti-VEGF therapies are becoming central to multidisciplinary treatment approaches, improving quality of life and long-term outcomes for millions.

What Are the Main Forces Driving Global Growth in the Anti-VEGF Therapeutics Market?

The growth in the Anti-VEGF therapeutics market is driven by a convergence of clinical need, demographic momentum, technological innovation, and market expansion strategies. A primary driver is the growing burden of retinal diseases and solid tumors, both of which are major public health challenges worldwide. The ability of anti-VEGF therapies to deliver measurable improvements in vision and tumor suppression has established them as gold-standard treatments across numerous indications. Strong R&D pipelines supported by leading pharmaceutical companies continue to bring new and improved agents to market, extending product life cycles and reaching new patient populations. Regulatory support, including fast-track approvals and orphan drug designations, is accelerating time-to-market for novel formulations, especially in rare eye conditions and resistant cancers. The rise of biosimilars is expected to democratize access by lowering treatment costs, particularly in developing countries where the economic burden of branded biologics remains a barrier. Strategic partnerships between biotech firms and major healthcare providers are helping to expand distribution networks and integrate anti-VEGF drugs into broader treatment algorithms. Additionally, increased patient awareness, the growing popularity of digital health platforms, and the shift toward value-based care are aligning incentives for early diagnosis and continuous treatment. Technological enablers such as AI-driven imaging and real-time data monitoring are further enhancing treatment precision and effectiveness. As a result of these interconnected forces, the global anti-VEGF therapeutics market is on a strong growth trajectory, poised to expand significantly in both scope and scale over the next decade.

SCOPE OF STUDY:

The report analyzes the Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease, Age-Related Macular Degeneration Disease); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Alcon Inc.
• Allergan plc
• Amgen Inc.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• Coherus BioSciences, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Wet AMD, DME, and Cancer Throws the Spotlight on Anti-VEGF Therapies
  • OEMs Offering Longer-Acting Intravitreal Injections Reduce Treatment Burden in Retinal Disorders
  • Use in Oncology for Inhibiting Tumor Angiogenesis Expands Indications Beyond Ophthalmology
  • Growth in Biosimilars and Alternative Delivery Methods Enhances Market Accessibility
  • OEM Focus on Port Delivery Systems and Implantable Devices Extends Dosing Intervals
  • Expansion of Personalized Medicine Drives Patient-Specific VEGF Inhibitor Selection
  • Use in Diabetic Retinopathy and Retinal Vein Occlusion Enhances Clinical Breadth
  • OEM Development of Topical and Systemic Anti-VEGF Options Drives Pipeline Innovation
  • Increased Global Screening for Eye Conditions Spurs Early and Sustained Treatment Adoption
  • Integration With Optical Coherence Tomography (OCT) Enables Precision Dosing Decisions
  • OEMs Targeting Reduced Inflammation and Immune Activation Improve Tolerability
  • Growth in Multi-Target Biologics Combining VEGF With Other Pathways Expands Future Potential
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Macular Edema Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Macular Edema Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Macular Edema Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Diabetic Retinopathy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Diabetic Retinopathy Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Retinal Vein Occlusion Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Retinal Vein Occlusion Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Age-Related Macular Degeneration Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Age-Related Macular Degeneration Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Age-Related Macular Degeneration Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: India 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION